ArticleAnnals of medicine2026

Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping and dynamic trajectories.

Xiang Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.